Taltz Plus Zepbound Yields 31.7% ACR50 and 84.5% Weight Loss in PsA Trial
In the Phase 3b TOGETHER-PsA trial, Taltz with Zepbound achieved 31.7% ACR50 plus ≥10% weight loss versus 0.8% with Taltz alone, and 84.5% versus 4.5% for ≥10% weight reduction. Combined therapy increased Minimal Disease Activity attainment to 26.3% versus 15.3% and improved fatigue scores by 8.6 versus 4.8 points.
1. Trial Design and Patient Population
The TOGETHER-PsA study is a 52-week, open-label Phase 3b trial enrolling adults with active psoriatic arthritis and obesity or overweight plus at least one weight-related comorbidity. Participants had an average BMI of 37.6 kg/m², high baseline disease activity, impaired physical function, and over 60% had prior advanced therapy exposure.
2. Efficacy Results at Primary Endpoint
At Week 36, the combination of ixekizumab (Taltz) and tirzepatide (Zepbound) achieved 31.7% of patients meeting ACR50 plus ≥10% weight reduction versus 0.8% with Taltz alone. Additionally, 33.5% achieved ACR50 (versus 20.4%) and 69.7% reached ACR20 plus ≥5% weight loss (versus 10.3%).
3. Secondary Outcomes and Patient-Reported Measures
Combined therapy drove 84.5% of patients to ≥10% weight loss versus 4.5% on monotherapy, and increased Minimal Disease Activity rates to 26.3% from 15.3%. Patients also reported greater fatigue improvement (8.6 vs 4.8 points), mental health gains (3.1 vs 0.4 SF-36 MCS points) and reductions in hsCRP, BMI, systolic blood pressure, glucose, HbA1c, triglycerides and total cholesterol.
4. Safety Profile and Next Steps
Adverse events with combined administration were generally mild to moderate and aligned with known profiles, most commonly including nausea, diarrhea, constipation and injection site reactions. Detailed findings will be reviewed with regulators to inform potential label updates and broader clinical use strategies.